IDEAYA Biosciences, a Phase 1 biotech developing targeted immunotherapies for cancer, filed on Friday with the SEC to raise up to $70 million in an initial public offering.
The South San Francisco, CA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol IDYA. IDEAYA Biosciences filed confidentially on January 17, 2019. J.P. Morgan, Citi and Jefferies are the joint bookrunners on the deal. No pricing terms were disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.